

Index

a

- absorption, distribution, metabolism, and excretion (ADME) 49, 55–57
- accompanying product 15
- acetophenones, of 2-arylpyridines synthesis from 209–211
- acetylcholine 46–47
- acetyl-CoA carboxylase (ACC) inhibitors 151
- acetylsalicylic acid 60
- acid 18
- acid–base reaction 19–20
- acid dissociation constant (pK_a) 19
- acid ionization constant. *see* acid dissociation constant (pK_a)
- acidity 19
- acidity constant. *see* acid dissociation constant (pK_a)
- acid promoted cyclization, morphine core construction by 157–158
- activators 45, 48
- active pharmaceutical ingredients (APIs) 26, 58–59, 305
- acyloin rearrangement in gibberellin 283–284
- adverse outcome pathways (AOPs) 57
- affinity 53–54
- agonists 47
- alcohol 306–312
 - hydrazines preparation from 102–103
 - thiourea-mediated conversion of alcohols to alkylhalides 74–76
- aldehydes
 - cyclization of diazo compound with 276–277
 - 1,2,4-trioxanes synthesis from 172–173
- alkyl aryl ketones 81
 - conversion to α -arylalkanoic acids 80–81
- alkylhalides, thiourea-mediated conversion of alcohols to 74–76
- 4-alkylphenols, 1,2,4-trioxanes synthesis from 172–173
- 3-alkylquinazolin-4-ones by Mukaiyama Reagent, synthesis of 269–270
- α -amination of amides 83–85
- α -Amino acids 83
- α -arylalkanoic acids, alkyl aryl ketone conversion to 80–81
- α -oxidation of amides 85–87
- amides
 - α -amination of 83–85
 - α -oxidation of 85–87
- amidino-diol side product 310–312
- amines 312–316
 - hydrazines preparation from 101–102
- aminophosphonate, synthesis of 97–98
- 4-(3-aminopropyl)-5-amino-1-methylpyrazole, synthesis of 227–229
- 2-aminopyridine motif 203
- amino pyrrole impurity formation 338–341
- 2-aminopyrroles, preparation of 180–182
- amplification 46
- anhydrous DCM 112–113
- aniline 20, 349–350
 - impurity formation by Smiles rearrangement 314–316
- anisole, bromination of 24
- annulation of ketones 191–192
- antagonists 47
- antibody drug conjugates (ADCs) 62
- 8a-Phenylloctahydroquinolin-4a(2H)-ol, preparation of 159–160
- aprepitant 306
- area under plasma drug concentration–time curve (AUC) 57
- aromatic amines 78–80
- aromatic bromides into aromatic nitriles, transformation of 90–91

Overcoming Synthetic Challenges in Medicinal Chemistry: Mechanistic Insights and Solutions, First Edition. Tongshuang Li.

© 2026 Wiley-VCH GmbH. Published 2026 by Wiley-VCH GmbH.

- aromatic compounds formation 122–126, 318–320
- aromatic ketones, preparation of
2-arylacetonitriles from 95–96
- aromatic nitriles, transformation of aromatic bromides into 90–91
- aromatic nitro compounds 124–125
- Arrhenius bases 18
- artemisinin 32
industrial-scale synthesis of 173–175
- artesonate 32
- artificial intelligence (AI) 49
- arylaceto-hydrazone nitrile, synthesis of 103–105
- 2-arylacetonitriles from aromatic ketones, preparation of 95–96
- arylacetonitriles from arylbromides, preparation of 89–90
- arylbromides, arylacetonitriles preparation from 89–90
- 2-aryl-N-benzylbenzimidazoles, synthesis of substituted 213–215
- ascomycin rearrangement 281–283
- aspirin 60
- asymmetric reactions 22
- asymmetric synthesis 13
- atom economy 30–31
- atropurpuran 33
- Austedo® (deuterated tetrabenazine) 61–62
- 7-aza-indazoles by Diels-Alder/
Retro-Diels-Alder Cascade 260–262
- AZD-7762 186
- aziridine 320–323
- b**
- Baeyer–Villiger oxidation 21
- base 18–19
- benzaldehyde 82–83
- benzene 192–197, 318–320
- benzene-1,3,5-triol, methylation of 24
- benzhydrocodone 61
- benzils, phenytoins preparation from 163–164
- benzofuran 356–361
- benzoxazolinone 361–362
- benzyl halides 74
- β -Aryl- α -keto acid, synthesis of 82–83
- β -hydroxycarboxylic acid, decarboxylative elimination of 134–137
- bicyclic aromatic heterocycle formation 248–277, 356
benzofuran 356–361
benzoxazolinone 361–362
naphthyridine 368–370
- pteridine 370–372
- quinoline 363–368
- Biginelli reaction 29
- bioavailability 57–58
- Birum–Oleksyszyn reaction 97–98
- boronate 89
- Bristol-Myers Squibb Company 10
- bromination of anisole 24
- 1-bromo-4-methoxybenzene 24
- Brønsted–Lowry acid 18
- Brønsted–Lowry bases 18
- Bucherer–Bergs reaction 29
- building blocks 34
- by-product 15
- BzNCS 332–333
- C**
- Cadogan reductive cyclization 257–259
- C-2 amination of pyridine 203–205
N-oxide derivatives 205–207
- cannabicitran 284–286
cannabichromene, cannabicitran formation during synthesis of 284–286
- caprolactam 196
- carbanions 16
- carbenes 16
- carboline to quinolone, oxidative rearrangement of 254–257
- carbon dioxide mediated synthesis of quinazoline-2,4(1H,3H)-dione 266–268
- carbonium ions 16
- carbonyl compounds, 1,2,4-trioxanes formation from 170–172
- carbonyldiimidazole (CDI) 332–333
CDI-promoted cyclization, impurities formation during 332–334
- cascade reaction 27–28
- catalyst 17
- catalytic reactions 14, 17
- ceftibuten synthesis, thiazole preparation from sulfoxide during 223–224
- cell surface receptors 46
- cephem 376–378
- charge balance. *see* electron balance
- checkpoint kinase 1 (Chk1) 186
- chemical species 17
- chemistry, manufacturing, and controls (CMC) 64
- chemokine receptor 5 (CCR5) 47
- chemoselectivity 20–21
- chiral (R)-5-(hydroxymethyl)-3-aryloxazolidin-2-one, preparation of 164–165
- chloromethane 11

- 5-chloro-3-phenylbenzo(c)isoxazole, formation of 217–219
- chromeno(3,2-i)quinolizine, preparation of 162–163
- circular chemistry 31
- cis*-2-(methoxycarbonyl)cyclopentane-1-carboxylic acid, preparation of 117–119
- cis*-*trans* isomers 22
- click chemistry 36–37
- clinical trials 65–66
- clobetasol propionate, impurity F formation of 372–373
- clog P 54
- clopidogrel (Plavix) 60
- combinatorial chemistry 38–39
- commercial stability 59
- computational methods 49
- computer-aided drug design 48
- continuous flow processing. *see* flow chemistry
- contract research organization (CRO) 65
- conventional heating 363–365
- convergent synthesis 34–35
- corticotropin-releasing factor receptor 1 (CRF1) 10
- cortisol 47
- Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 37
- Current Good Manufacturing Practices (cGMP). *see* Good Manufacturing Practices (GMP)
- CXCR4 47
- cyanomethylenetributylphosphorane (CMBP) 87
- cyclic alkane and derivatives formation 105–122, 316–318
- cyclic mechanism 14
- cyclic peroxides, 1,2,4-trioxane formation from 170–172
- cyclization of diazo compound with aldehyde 276–277 formation of hexasubstituted benzene ring by 122–124 of γ -ketonitrile 183–186 [3+2] cycloaddition by sulfur extrusion 272–273
- cyclobutane 115 3-ethylbicyclo[3.2.0]hept-3-en-6-one, synthesis of 115–117
- cycloheptane 120 homobenzylic ketones, preparation of 120–122
- cyclopentane 117 *cis*-2-(methoxycarbonyl)cyclopentane-1-carboxylic acid, preparation of 117–119 rearrangement of furfuryl alcohol to 4-hydroxy-2-cyclopentenone 119–120
- cyclopropane 105–115, 316–318 formation by dialkylation of active methylene 109–111 ring in nucleophile substitution on steroid, formation of 277–280 ring-opening reaction 144–146 tandem cyclopropanation ring-expansion reaction 111–115
- cyclopropylamines, synthesis of 107–109
- cystic fibrosis transmembrane (CFTR) corrector 205
- cytoplasmic receptors 46
- ## d
- darunavir 48
- Davis-Beirut reaction, synthesis of indazole by 262–265
- dealkylation of tertiary amine with DEAD 153–155
- decision-making ability 6–7
- dehydrohalogenation of 2-iodobutane 23
- demethoxycarbonylation of malonate 373–374
- D-erythronolactone from erythorbic acid, preparation of 129
- design of experiments (DoE) model 343
- desired product 14
- Dess–Martin oxidation 21
- deucravacitinib 62
- deuterated drugs 61
- deuterium-containing drug 61–62
- dexrazoxane, pteridine impurities formation during synthesis of 370–372
- dialkylation of imine 110
- 1,4-diazabicyclo(2.2.2)octane (DABCO) 365
- 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) 193, 225
- diazepine 167–170, 355–356
- diazo compound with aldehyde, cyclization of 276–277
- dibenzo(c,f)-2,7-naphthyridine-3,6-diamine, unexpected formation of 368–370
- 1,2-dichlorobenzene, tetralone synthesis from 125–126
- 1,2-dichloroethane 9
- dichloromethane (DCM) 75
- Diels–Alder reaction 22, 30
- Diels–Alder/Retro-Diels–Alder Cascade, synthesis of 7-aza-indazoles by 260–262
- diene 22
- diethyl azodicarboxylate (DEAD) 80
- diethylaminosulfur trifluoride (DAST) 324

- difluoro alkyl branch 4
 2-(2,6-difluorophenyl)-4-(*p*-tolyl)oxazole
 formation 346–349
 dihydroartemisinin 32
 3-(3,4-Dihydro-2*H*-pyrrol-5-yl)pyridine,
 synthesis of 182–183
 diketone E 359
 dimerization of terminal aziridines to
 (*E*)-but-2-ene-1,4-diamines 72–74
 2,4-dimethoxybenzyl (DMB) 9
 dimethylamine (DMA) 84, 356
 4-(dimethylamino)pyridine (DMAP) 349
 dimethylcarbamoyl-Obt in HBTU-promoted
 amide preparation 351–353
 dimethylformamide (DMF) 23
 dimethylmalononitrile (DMMN) 93
 2,2-dimethyl-5-phenylfuran-3(2*H*)-one
 133–134
 dimethyl sulfoxide (DMSO) 89
 Dimroth rearrangement 270–271
 2,4-dinitrobenzenesulfonamide (DNBSA) 91
 dipeptide 38
 direct drug design. *see* structure-based
 drug design
 direct oral anticoagulant (DOAC) 320
 discovery chemists. *see* medicinal chemists
 2,4-disubstituted imidazole, formation
 of 212–213
 2,3-disubstituted indole, formation
 of 248–250
 disubstituted malononitriles, synthesis
 of 92–94
 1,1'-disubstituted olefins 120–122
 divergent synthesis 36
 domino reaction. *see* cascade reaction
 drug 43
 candidate 55
 discovery 43–44
 fetcher 1
 stability 59
 target 45
 drug design 48–49
 drug metabolism and pharmacokinetics
 (DMPK) 57
- e**
 (*E*)-but-2-ene-1,4-diamines, dimerization of
 terminal aziridines to 72–74
 efficacy 53–54
 electron balance 18
 electrophile 18
 enamine 81
 enantiomer excess (ee) 22
 enantiomers 22
- endogenous ligand 46
 5-*endo-tet* process 360
 6-*endo-tet* process 359
 enzyme-linked hormone receptors 46
 enzymes 45–46
 erlotinib, Dimroth rearrangement in
 preparation of 270–271
 erythorbic acid, D-erythronolactone
 preparation from 129
 esaxerenone 183
 estrogen-related receptor 1 (ERR1) 323
 ethacrolein 22
 ethyl acetate 5
 3-ethylbicyclo[3.2.0]hept-3-en-6-one, synthesis
 of 115–117
 ethylene carbonate 367
 ethyl 3-(trifluoromethyl)pyrazine-
 2-carboxylate, synthesis of 237–239
 excess reagents 16
 excipients 59
 expected product. *see* desired product
 extended Dimroth rearrangement 273–274
- f**
 Favorskii rearrangement 373
 FCN-159 211
 flow chemistry 29–30
 flow process 27
 Food Drug Administration (FDA) 32, 45
 formal synthesis 32–33
 formulation 58–59
 2-formylpyrroles from pyridinium iodide salts,
 synthesis of 179–180
 fosdenopterin core construction 137–138
 free radicals 16–17
 Friedel-Crafts acylation 369
 furfuryl alcohol to 4-hydroxy-
 2-cyclopentenone, rearrangement
 of 119–120
- g**
 γ -ketonitrile, formation of substituted pyrrole
 by cyclization of 183–186
 gas chromatography-mass spectrometry
 (GC-MS) 75
 gefitinib, Dimroth rearrangement in
 preparation of 270–271
 geometric isomers 23
 geranyl-6-formyl-4-methoxycarbonyl-5-
 pivaloyloxymethyl resorcinol 122–123
 gibberellins (GAs) 283
 acyloin rearrangement in 283–284
 glucan synthase (GS) inhibitors 124

- glucokinase and glucokinase regulatory protein (GK-GKRP) 71
- Good Laboratory Practices (GLP) 55, 62–63
- Good Manufacturing Practices (GMP) 63–64
- G protein-coupled receptors (GPCRs) 46–47
- G protein-linked receptors 47
- green chemistry 31–32
- Grignard reaction, unexpected impurity from 306–308
- GS-9131. *see* *Rovaflovir etalafenamide*
- h**
- half-maximal effective concentration (EC₅₀) 53–54
- heteroaromatic-fused pyrrolidines, synthesis of 144–146
- heteronuclear multiple bond correlation (HMBC) 335
- hexasubstituted benzene ring by cyclization, formation of 122–124
- HFIP catalyzed cyclization 197–198
- high-performance liquid chromatography (HPLC) 5, 82, 307
- high-resolution mass spectrometry (HRMS) 317
- high-throughput screening (HTS) 43, 51–52
- 2*H*-indazoles 257
- hit-to-lead (H2L) stage 52
- homobenzylic ketones, preparation of 120–122
- 2-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)acetates, one-pot synthesis of 274–276
- Huisgen 1,3-dipolar cycloaddition 37
- human immunodeficiency viruses (HIV) 47
- hydrazine derivatives formation 101–105
- hydrofuran 133–137
- decarboxylative elimination of β -hydroxycarboxylic acid 134–137
- hydrogen carbonate 367
- hydrogen in aromatic nitro compounds 124–125
- hydrophobicity 54
- 4-hydroxy-2-cyclopentenone, rearrangement of alcohol to 119–120
- 2-hydroxyethyl from indole derivative, deprotection of 252–253
- 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 45
- 3-hydroxy-3-methylglutaryl (HMG) reductase 45
- 4-hydroxyphenyl 328
- 21-hydroxypregna-4, 9(11), 16-triene-3,20-dione-21-acetate, preparation of 280–281
- 5-hydroxypyrimidin-4(3*H*)-one, formation of 229–231
- 2-hydroxyquinoline-4-carboxylic acids 364
- 8-hydroxyquinoline, tricyclic impurity during alkylation of 365–368
- i**
- imidazoline 163
- phenytoins preparation from benzils 163–164
- ring 329
- imine, dialkylation of 110
- impurities 15, 305
- indazole 257–271
- indirect drug design. *see* *ligand-based drug design*
- indole 248
- 2,3-disubstituted indole, formation of 248–250
- by vinyl Grignard reagent with nitroarenes 250–252
- indolizine 254
- industrial-scale synthesis of artemisinin 173–175
- industrial synthesis of orotic acid 232–234
- inhibition constant 53
- inhibitors 45, 47–48
- inorganic compounds 45
- integration 46
- intermediates 16
- internal alkyne, isomerization of 71–72
- intracellular receptors 46
- Investigational New Drug (IND) Application 65
- in vitro testing 55
- in vivo testing 55
- iodine-mediated cyclization of 2-pyridylallenes 254
- 2-iodobutane, dehydrohalogenation of 23
- 2-iodoindolizines, iodine-mediated cyclization of 2-pyridylallenes 254
- IPI-926. *see* *saridegib*
- ipso-selective nitrene internalization 192–197
- isatins 364
- isolable intermediates 322
- isomerization of terminal alkyne to internal alkyne 71–72
- isopropanol 368
- 1-isopropenyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one 216–217
- isopropyl alcohol (IPA) 228
- isopropyl carbonate 365
- isopropyl ether (IPE) 228
- isoxazole 217–221

iteromers 24
 iteroselective monomethylation of diol 5
 iteroselectivity 23–25

k

K₂CO₃ 349
 ketoamine formation 312–314
 ketones, annulation of 191–192

l

lactone 126–133, 375–376
 lead(IV) acetate, oxidative decarboxylation of
N-aroylglycines with 76–78
 lead compound 51
 lead generation. *see* hit-to-lead (H2L) stage
 lead optimization (LO) 51
 Lewis acid 18
 Lewis bases 18
 Librium, accidental discovery of 355–356
 ligand 46
 ligand-based drug design 49
 ligand-gated ion channels 46
 limiting reagents 16
 linear mechanism 14
 linear synthesis 34–35
 Lipinski's Rule of Five 49–51
 lipophilic efficiency 49
 lipophilicity 54
 liposidomycin 334
 liquid chromatography mass spectrometry
 (LCMS) 321
 lithium methyl borohydride 22
 L-lyxonolactone-2,3-*O*-isopropylidene,
 synthesis of 129–131
 lofexidine 329–331
 log P 54
 lorlatinib 306
 lovastatin 45
 lusutrombopag 306
 2,6-lutidine *N*-oxide (LNO) 85

m

macrolides 51, 281–283
 malonic acid 235–237, 364
 Maraviroc 47
 mass balance. *see* material balance
 material balance 17
 medications 43
 medicinal chemistry 2, 43–45
 medicinal chemists 39–40
 mesityl oxide 355
 metallodrugs 45
 methanesulfonate (MsO) 207
 methotrexate 48

methoxatin 245
 3-methoxy-1-propanol 5
 methyl acrylate 36
 methylamine 10, 311–312, 355
 2-methylanilines, indazole preparation
 from 259–260
 methylation of benzene-1,3,5-triol 24
 24-methylene steroidal impurity, formation
 of 373–375
 methyl iodide, terramycin unusual reaction
 with 375–376
 1-methylpyrimidine-2,4,6(1*H*,3*H*,5*H*)-trione,
 regioselective chlorination of 231–232
 methyl (1*S*,5*R*)-2-oxo-3-
 oxabicyclo[3.1.0]hexane-1-
 carboxylate 105–107
 methyl *tert*-butyl ether (MTBE) 97, 311
 mirogabalin besylate 115
 mistakes in synthetic organic chemistry 2–6
 Mitsunobu reaction 31
 Tsunoda reagent for 87–89
 molnupiravir 26
 monoalkylation of primary amines 25
 monoclonal antibody (mAb) 62
 monocyclic aromatic heterocycles
 formation 175–248, 338–356. *see also*
 bicyclic aromatic heterocycle formation
 monoprotected ethylene diamine 25
 montmorillonite K-10 28
 morin, benzofuran side products during
 synthesis of 356–361
 morphine core by acid promoted cyclization,
 construction of 157–158
 M1-type muscarinic acetylcholine
 receptors 349
 Mukaiyama reagent, 3-alkylquinazolin-
 4-ones synthesis by 269–270
 multicomponent reactions (MCR) 27, 29
 multisubstituted pyridines
 preparation of 199–201
 synthesis of 197–198

n

1-naphthol, synthesis of tetralone
 from 125–126
 2,7-naphthyridin-3(2*H*)-one 9
 naphthyridine 368–370
N-bromocaprolactam (NBC) 193
N-bromosuccinimide (NBS) 75
N,2-dihydroxybenzamide, formation
 of undesired benzoxazolinone
 from 361–362
 net yield 16
 New Drug Application (NDA) 44, 66–67

- N*-halosuccinimides (NXS) 75
 nirmatrelvir 46
 nitriles from carboxylic acid, preparation of 91–92
 nitroarenes 124–125
 nitro compounds, isoxazole preparation from 219–221
N-methyl-2-pyrrolidone (NMP) 245
N-methylmorpholine (NMM) 11
N,N-dibromo-*p*-toluenesulfonamide (TsNBr₂) 24
N,N'-dicyclohexylbarbituric acid from DCC and malonic acid, preparation of 235–237
N,N'-dimethylthiourea (DMTU) 75
N,N-diphenethylaniline 15
N,O-bis-(trimethylsilyl) acetamide (BSA) 205
 nonaromatic heterocycles formation 126–175, 320–338
 noncatalytic reactions 14
 nonclinical studies. *see* preclinical studies
 noncyclic alkane formation and derivatives 306–316
 noncyclic compounds formation 71–100
N-phenethylaniline 15
N-phosphorylated amidine 81
N-sulfinyl-*O*-(*tert*-butyl)hydroxylamine (*t*-BuONSO) 98–100
 nuclear magnetic resonance spectroscopy 50
 nuclear Overhauser effect spectroscopy (NOESY) 335
 nuclear receptors 46
 nucleic acids 45
 nucleophile 18
 nucleophilic cyanation of pyridines 207–209
- O**
- octahydroquinolizine, preparation of 160–161
 olmesartan medoxomil (OLM) 353
 omeprazole (Prilosec) 60
 omidenepag isopropyl 61
 one-pot multicomponent reaction, preparation of spiro 1*H*-pyrrol-2(5*H*)-ones by 188–190
 one-pot reactions 16
 one-pot synthesis 25–27
 of 2-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl) acetates 274–276
 Oppenauer oxidation process 307
 optimal synthetic design, combining literature and insight for 6
 organic chemistry 2
 organic compounds 44
- organometallic compounds 45
 orotic acid (OA) 232
 industrial synthesis of 232–234
 overall yield 16
 oxadiazole 240–243
 1,3,4-oxadiazole, formation of 240–241
 1,2,4-oxadiazole, preparation of 241–243
 oxathiolane 175–177
 oxaziridines, preparation of hydrazines from amines by using 101–102
 oxazole 346–351
 oxazolidine 164–165
 oxazoline impurity in synthesis of M1 agonist 349–351
 oxetanes, isoxazole preparation from 219–221
 oxidative decarboxylation of *N*-aroylglycines with lead(IV) acetate 76–78
 ozonides, thermal rearrangement of 131–133
- P**
- parallel synthesis 37
 partial synthesis 32–33
 partition coefficient 54
 patents 8
 paxlovid 46
penta-substituted pyridine, preparation of 211–212
 peptides 51
 percentage yield 16
 4-perfluoroalkylpyridines, preparation of 201–203
 peripheral neuropathic pain (PNP) 115
 peroxisome proliferator-activated receptor (PPAR)- α 316
 Pfitzinger reaction conditions 363–365
 Pfizer's Rule of Five. *see* Lipinski's Rule of Five
 pharmacodynamics (PD) 55–56
 pharmacokinetics (PK) 50, 55–56
 pharmacology 58
 pharmacophore 52–53
 phase I studies 65
 phase IV studies 66
 phase II-a trials 66
 phase II-b trials 66
 phase III trials 66
 phenol 4
 phenytoins preparation from benzils 163–164
 phloroglucinol. *see* benzene-1,3,5-triol
 piperazine 356
 piperidine 148–163, 326–329
 polo-like kinase1 (Plk1) binding inhibitors 219
 polycyclic aromatic heterocycles formation 248–277

potassium cyanide (KCN) 218
 potassium hydride (KH) 91
 potassium methoxide 218
 potassium thiocyanate (KSCN) 244
 potency 53–54
 preclinical studies 55
 preformulation 58
 pre-market stability 59
 primary sulfonamide, synthesis
 of 98–100
 process chemistry 305
 process chemists 39–40
 prodrugs 60–61
 2-propanol 342
 protein kinases 46
 proteins 44
 δ -keto- α -amino acids, novel synthesis
 of 155–157
 pteridine 370–372
p-toluenesulfonic acid 15
 pyrazine 237–239
 pyrazole 224–229, 343–346
 pyrazolopyrimidine 276
 cyclization of diazo compound with
 aldehyde 276–277
 pyridine 191–212, 341–343. *see also*
 multisubstituted pyridines
 pyridinium iodide salts, 2-formylpyrroles
 synthesis from 179–180
 pyridopyrimidine 273–274
 2-pyridylallenes 254
 pyridyl to hydroxyl from sulfone during
 alkylation 341–343
 pyrimidine 229–237
 pyrimidine-2,4(1H,3H)-dione, 2-Thioxo-
 2,3-dihydropyrimidin-4(1H)-one
 to 234–235
 pyrrole 177–186, 338–341
 pyrrole-2-aldehyde, preparation
 of 177–178
 pyrrole-2-*t*-butyl ester, preparation
 of 177–178
 pyrrolidine 80
 2,5-Dibenzyltetrahydropyrrolo
 [3,4-*c*]pyrrole-1,3-dione, formation
 of 138–148
 enamine 81
 ring-contracted side product during
 fluorination, formation of 323–326
 pyrrol-2-one 188–190
 pyrrolopyrimidine 274
 one-pot synthesis of 2-(7H-pyrrolo[2,3-*d*]
 pyrimidin-4-yl) acetates 274–276

q

quantitative structure–activity relationship
 (QSAR) 44, 49, 54
 quinazoline 265
 carbon dioxide mediated synthesis of
 quinazoline-2,4(1H,3H)-dione 266–268
 synthesis of 265–266
 quinazoline-2,4(1H,3H)-dione, carbon dioxide
 mediated synthesis of 266–268
 quinazolinones 269
 quinoline 363–368
 quinoline-4-carboxylic acids 363–365
 quinolone 254
 oxidative rearrangement of carboline
 to 254–257

r

racemic mixture 22
 raloxifene 47
 rational design. *see* drug design
 rational drug design. *see* drug design
 reaction mechanism 7–8, 13–14
 reaction selectivity 20
 Reaxys 6
 receptors 45–47
 regioselective chlorination of
 1-methylpyrimidine-2,4,6(1H,3H,5H)-
 trione 231–232
 regioselectivity 21
 Rinskor 199
 ritonavir 46
 Rovafovir etalafenamide 134
 RRT 0.49 impurity, preparation and
 purification of 372–373
 Rule of Five (RO5). *see* Lipinski's Rule of Five

S

salt carbonate 367
 samidorphan 157
 saridegib 111
 SB-462795 341
 SciFinder 6
 selectivity 20
 semi-synthesis. *see* partial synthesis
 Semmler–Wolff aromatization, ketoamine
 formation during 312–314
 serdexmethylphenidate 61
 serratezomine 287–288
 serratezomine A, serratinine transformation
 into 287–288
 side products 15, 305
 side reaction 15

- 3,3-sigmatropic rearrangement,
5-hydroxypyrimidin-4(3*H*)-one formation
by 229–231
- signal relay 46
- Smiles rearrangement, preparation of nitriles
from carboxylic acid by 91–92
- sodium hydride 346
- solid-phase synthesis 38
- species 17
- spiro[3*H*-indole-3,2'-pyrrolidin]-2(1*H*)-one,
synthesis of 146–148
- spiroperidine,
preparation of 151–153
- spiro 1*H*-pyrrol-2(5*H*)-ones
preparation 188–190
- stereochemistry 13
- stereoselectivity 13, 21–23
- steroid 277–281, 372–375
- stoichiometric reaction 17
- structure-activity relationship (SAR)
studies 39, 44, 54
- structure-based drug design 48, 50
- substituted 2-aryl-*N*-benzylbenzimidazoles,
synthesis of 213–215
- substituted 1,3-oxathiolane, synthesis
of 175–177
- substituted pyrrole by cyclization of
 γ -ketonitrile 183–186
- 6-sulfamoylquinoline-4-carboxylic acids,
general procedure for synthesis
of 363–365
- sulfoxide, preparation of thiazole
from 223–224
- sulfur extrusion
[3+2] cycloaddition by 272–273
pyrazole preparation by 226–227
- sustainable chemistry 31
- Suzuki cross coupling 13
- Swern oxidation 21
- symmetrical carbonate 365
- synthetic organic chemistry 1, 13
art as science 1–2
decision-making ability 6–7
examples 9–12
experimental science 2
knowledge, experience,
and skills 3
mistakes 2–6
optimal synthetic design, combining
literature and insight for 6
patents 8
reaction mechanism 7–8
synthesis process 9
- t**
- tabersonine, preparation of vincamine
from 288–290
- TAK-733 211
- tandem cyclopropanation ring-expansion
reaction 111–115
- tandem reaction. *see* cascade reaction
- tautomerization 313, 372
- t*-BuOK promoted isomerization of terminal
alkyne to internal alkyne 71–72
- telescoped reactions 16
- telescoping process 25–27
- terminal alkyne to internal alkyne,
isomerization of 71–72
- terminal aziridines to
(*E*)-but-2-ene-1,4-diamines 72–74
- tetramycin 375–376
- tert-butyldiphenylsilyl chloride (TBDPSCl) 5
- tert-butyl hydroperoxide (TBHP) 357
- (tert-Butylimino) tris(pyrrolidino)phosphorane
(BTTP) 342
- tert-butylmethyl ether (TBME) 110
- tertiary amine with DEAD, dealkylation
of 153–155
- tetrahydrofuran (THF) 71, 317
- 2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]
diazepine, synthesis of 167–170
- tetrahydropyran 137–138
- tetrahydropyrazine 329
unexpected tetrahydropyrazine product,
formation of 329–332
- tetrahydropyrimidine
CDI-promoted cyclization, formation of
impurities during 332–334
tetrahydropyrimidinol, synthesis
of 166–167
- tetrahydropyrimidinol, synthesis
of 166–167
- tetrahydroquinoline 336
unexpected tetrahydrobenzoquinoline side
product formation 336–338
- tetralone synthesis 125–126
- tetrazole 353–355
- theoretical yield 16
- therapeutic index 56
- therapeutic ratio 56
- thiadiazole 243–245
- 1,2,4-thiadiazole, formation of 243–245
- thiazole 221–224
- thienoquinolizine 272–273
- thin-layer chromatography (TLC) 5, 79, 335
- thiolactone preparation from
lactone 126–128

- thiophene 186–188
- thiourea-mediated conversion of alcohols to alkylhalides 74–76
- thiourea, thiazole preparation by 221–222
- 2-thioxo-2,3-dihydropyrimidin-4(1H)-one to Pyrimidine-2,4(1H,3H)-dione 234–235
- titanium isopropoxide 330
- toluene 330
- total synthesis 32–33
- toxicity 56
- toxicology testing 55
- trametinib 273
- trans*-3-substituted proline derivatives, synthesis of 139–141
- transition state 17
- transmembrane receptors. *see* cell surface receptors
- triazine 245–248
- 1,2,3-triazines, synthesis of 245–248
- triazole 239–240, 351–353
- 1,2,3-triazole 37
- [1,2,4]triazolo[1,5-a]pyridin-2-amine, preparation of 239–240
- 1,3,5-tribromo-2-methoxybenzene 24
- tricyclic compound 365, 367
- tricyclic impurity during alkylation of 8-hydroxyquinoline 365–368
- triethanolamine 332
- triflate group (TfO) 84
- trifluoroacetic acid (TFA) 98
- trifluoromethylpyrazoles, synthesis of 224–226
- trimethylamine 321
- trimethylsilyl trifluoromethanesulfonate (TMSOTf) 334–335
- trioxane 170–175
- 1,2,4-trioxanes 170–172
- from 4-alkylphenols and aldehydes, synthesis of 172–173
- 3,4,8-trisubstituted quinoline derivatives 365
- trisubstituted thiophene, synthesis of 186–188
- Tsunoda reagent for Mitsunobu reaction 87–89
- type I prodrugs 60
- type II prodrugs 60
- U**
- Ugi reaction 29
- ultraviolet (UV) absorption 5
- undesired products 305
- unexpected product 14
- V**
- vemurafenib 180
- vicarious nucleophilic substitution of hydrogen 124–125
- vincamine 288
- preparation from tabersonine 288–290
- vinyl Grignard reagent with nitroarenes, novel synthesis of indoles by 250–252
- Vismodegib 209
- X**
- X-ray crystallography 50
- Xu's intermediate 33
- Y**
- yield 16